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The ubiquitin–proteasome system is essential for multiple physiological processes via
selective degradation of target proteins and has been shown to plays a critical role in
human cancer. Activation of oncogenic factors and inhibition of tumor suppressors have
been shown to be essential for cancer development, and protein ubiquitination has been
linked to the regulation of oncogenic factors and tumor suppressors. Three kinases, AKT,
extracellular signal-regulated kinase, and IκB kinase, we refer to as oncokinases, are acti-
vated in multiple human cancers. We and others have identiﬁed several key downstream
targets that are commonly regulated by these oncokinases, some of which are regulated
directly or indirectly via ubiquitin-mediated proteasome degradation, including FOXO3, β-
catenin, myeloid cell leukemia-1, and Snail. In this review, we summarize these ﬁndings
from our and other groups and discuss potential future studies and applications in the clinic.
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UBIQUITIN–PROTEASOME SYSTEM AND CANCER
In order to maintain cellular homeostasis, the amount of pro-
teins in cells is selectively controlled not only in protein synthesis
but also in protein degradation. The ubiquitin–proteasome path-
way is essential for multiple physiological systems via selective
degradation of target proteins (Hershko and Ciechanover, 1998).
The proteins designated for proteasome-mediated degradation are
conjugated with polypeptide of ubiquitin, which are then targeted
to 26S proteasome complex (Hochstrasser, 1995). Ubiquitination
of target protein is regulated throughmulti-enzymeprocesses in an
ATP-dependentmanner. First, the E1 protein, ubiquitin-activating
enzyme, activates ubiquitin, which is then transferred to the E2
protein. The E3 protein is an ubiquitin protein ligase that deter-
mines the substrate speciﬁcity. The RING ﬁnger-containing E3
ligase binds to its substrate and the ubiquitinated E2 protein and
then directly transfers the ubiquitin from the E2 protein to the
substrate (Lipkowitz and Weissman, 2011). On the other hand,
the HECT domain-containing E3 ligase can also receive ubiqui-
tin from the E2 protein ﬁrst through an active-site cysteine of
its HECT domain then interacts with its substrate to catalyze the
conjugation of the activated ubiquitin to the substrate (Kee and
Huibregtse, 2007). Since the speciﬁcity of the target proteins for
proteasome-mediateddegradation is dependent on the interaction
between the E3 ligases and their targets, the E3 ubiquitin ligases
are critical for regulating the expression levels of key short-lived
proteins.
Cancer is a genetic disease that is caused by multiple genetic
mutations. In cancer cells, oncogenic drivers that are frequently
mutated or overexpressed activate the signaling pathways to pro-
mote cell proliferation, growth, and survival while tumor suppres-
sors that are commonly inactivated bymutation or deletion inhibit
these pathways. It has been demonstrated that the expression
levels of some key oncoproteins and tumor suppressors are under
the control of ubiquitin–proteasome system with some E3 lig-
ases that function as oncogenic factors or tumor suppressors.
For example, MDM2 and Skp2 ubiquitinate and inhibit tumor
suppressors via proteasomal degradation, and thereby function
as oncogenic factors (Marine and Lozano, 2010; Wang et al.,
2011). In contrast, other E3 ligases such as the anaphase pro-
moting complex/cyclosome (APC/C) and F-box and WD repeat
domain-containing 7 (FBW7) serve as tumor suppressors by
downregulating oncogenic factors (Crusio et al., 2010;Wasch et al.,
2010).
Accumulating evidence indicates that ubiquitin–proteasome
pathways are potential drug targets for cancer therapy. For exam-
ple, bortezomib is a speciﬁc proteasome inhibitor that is cur-
rently used for the treatment of multiple myeloma. Moreover,
the inhibitors for speciﬁc E3 ligases have been also considered
as potential anti-cancer drugs. MDM2 is the primary ubiquitin
ligase for tumor suppressor protein, p53, which induces apoptosis
or senescence in response to oncogenic stress or DNA damage.
The p53 pathway is frequently inactivated in human cancer cells,
and the small molecules that block the interaction between p53
and MDM2 to inhibit p53 degradation have been tested in clin-
ical trials (Brown et al., 2009). Therefore, dissecting the speciﬁc
ubiquitin–proteasome signaling facilitating cancer progression
may contribute to the development of novel drug targets.
THREE SURVIVAL KINASES AND THEIR SIGNALING
PATHWAYS
Protein kinases and phosphatases catalyze the protein phospho-
rylation and dephosphorylation, respectively, which are essential
for maintaining signal transduction. When cells receive extracel-
lular signaling and stress, the signals are primarily transduced to
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the nucleus via protein phosphorylation, resulting in the alter-
ation of gene expression. For example, epidermal growth factor
(EGF) stimulates cell proliferation by binding to its receptor, EGF
receptor (EGFR), and activating it. EGFR is a receptor tyrosine
kinase that phosphorylates and activates multiple downstream
targets and promotes cell growth and survival. EGFR, consid-
ered as an oncogene, is frequently overexpressed or mutated in
multiple human cancers and promotes tumor progression,metas-
tasis, and drug resistance (Nicholson et al., 2001; Hynes and
Lane, 2005; Quatrale et al., 2011). Indeed, many oncoproteins
include protein kinases, and these oncogenic kinases phospho-
rylate downstream targets to promote tumor growth, metastasis,
and/or angiogenesis.
The serine/threonine kinase AKT is one of the major down-
stream kinases activated by growth factor signaling such as EGFR,
platelet-derived growth factor receptor (PDGFR), and insulin-like
growth factor receptor (IGFR). AKT has three isoforms, AKT1,
AKT2, and AKT3, and their activities are frequently elevated in
multiple human cancers, which contribute to cancer cell sur-
vival and growth (Altomare and Testa, 2005). AKT is activated by
phosphatidylinositol-3 kinase (PI3K) that converts phosphatidyli-
nositol (3,4)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) in plasma membrane through lipid phos-
phorylation (Altomare and Testa, 2005; Yuan and Cantley, 2008).
AKT and phosphoinositide dependent kinase 1 (PDK1) are then
recruited to the plasma membrane where AKT is directly phos-
phorylated and activated by PDK1 (Chan et al., 1999). Activated
AKT phosphorylates various substrates involved in cell metabo-
lism (GSK3, TSC2), survival (Bad, FOXO), and cell cycles (p21,
p27, MDM2; Cross et al., 1995; Datta et al., 1997; Brunet et al.,
1999; Zhou et al., 2001a,b; Liang et al., 2002;Manning et al., 2002),
and then inhibits apoptosis and promotes cell growth. Therefore,
the PI3K–AKT pathway is a potential drug target, and several PI3K
or AKT inhibitors have been actively tested in numerous clini-
cal trials (Garcia-Echeverria and Sellers, 2008; Wong et al., 2010;
Chappell et al., 2011).
Extracellular signal-regulated kinase (ERK) is another criti-
cal downstream kinase in growth factor signaling and plays an
essential role in cancer cell proliferation (Robinson and Cobb,
1997; Sebolt-Leopold, 2000). The Ras–Raf–MEK–ERK pathway
is a well-characterized signaling pathway and is commonly acti-
vated in multiple human cancers. Studies have shown that Ras
and Raf are frequently mutated in various human cancer types
and responsible for cancer progression (Adjei, 2001; Davies et al.,
2002). Therefore, this signaling pathway has been considered a
drug target for cancer therapy, and a variety of inhibitors have
been developed, including MEK or Raf inhibitors (Davies et al.,
2007; Bollag et al., 2010; Hatzivassiliou et al., 2010; Maurer et al.,
2011).
IκB kinases (IKKs) are the primary regulator of NF-κB, which
plays a key role in immune response, cell proliferation, and sur-
vival (Baldwin, 2001; Luo et al., 2005). IKKs are activated in
response to various cytokines and inﬂammatory stimuli such as
tumor necrosis factor (TNF)-α, interleukin-1, and lipopolysac-
charide. The IKK family includes IKKα, IKKβ, IKKγ, IKKε, and
TANK-binding kinase 1 (TBK1). Interestingly, IKKγ has no kinase
activity and functions as an adaptor protein for the canonical
IKK complex (Hacker and Karin, 2006). IKKs are involved in two
distinct pathways for NF-κB activation: the canonical and non-
canonical pathways. IKKβ plays a dominant role in the canonical
pathway and IKKα in the non-canonical pathway (Perkins, 2007;
Israel, 2010). In the canonical pathway, IKKα, IKKβ, and IKKγ
form a kinase complex that phosphorylates IκBα, an inhibitor
protein of NF-κB, and induces the ubiquitination and subse-
quent proteasome-dependent degradation of IκBα. In the non-
canonical pathway, IKKα forms a homodimer and phosphorylates
p100, and generates p52 by partial processing of p100, resulting
in the activation of p52/RelB. In contrast to IKKα and IKKβ,
IKKε and TBK1 play a role in the induction of interferon sig-
naling in response to viral infection (Shen and Hahn, 2011).
Although NF-κB has been known to be involved in the progres-
sion of various cancers, increasing evidence suggests that IKKs
also play vital roles in cancer independently of NF-κB (Lee and
Hung, 2008; Baud and Karin, 2009; Shen and Hahn, 2011). For
example, IKKα phosphorylates both estrogen receptor α (ERα)
and co-activator SRC3 and enhances ERα transcriptional activity
while IKKβ phosphorylates a tumor suppressor, tuberous sclerosis
1 (TSC1), and inhibits its function (Park et al., 2005; Lee et al.,
2007). IKKα also phosphorylates CBP and the phosphorylated
CBP preferentially interacts with NF-κB rather than p53, result-
ing in NF-κB activation as well as p53 inactivation (Huang et al.,
2007). Recently, we found that IKKα phosphorylates and inhibits
FOXA2. Inactivation of FOXA2 results in the decrease of NUMB
expression, and subsequent NOTCH activation (Liu et al., 2012).
Considering that inhibition of NF-κB may affect inﬂammatory
responses, IKKs may be the potential alternative drug targets for
cancer.
The above-mentioned three survival kinases play critical roles
in cancer cell survival, metabolism, proliferation, and growth.
Interestingly, these kinases have many common targets that they
directly or indirectly regulate. Moreover, we and others have iden-
tiﬁed several common targets of these three kinases that are reg-
ulated by the ubiquitin–proteasome system. We will discuss these
proteins one by one in the later next section of the review.
FORKHEAD BOX O
The forkhead box O (FOXO) family proteins are critical tran-
scription factors that are involved in the regulation of cell pro-
liferation, cell death, cell metabolism, and DNA repair (Tran
et al., 2003; Arden, 2008). FOXO family includes FOXO1, FOXO3,
FOXO4, and FOXO6, and is conserved from C. elegans to mam-
mals (Burgering, 2008; Calnan and Brunet, 2008). FOXO fam-
ily proteins directly activate multiple gene expression involved
in cell cycles, apoptosis, metabolism, and DNA damage repair,
such as p27kip, Bim, FasL, MnSOD, GADD45 (Dijkers et al.,
2000; Kops et al., 2002; Tran et al., 2002; Ciechomska et al.,
2003; Sunters et al., 2003). Moreover, it has been shown that
FOXO proteins are dysregulated in multiple human cancers such
as breast, prostate, leukemia, and glioblastoma (Hu et al., 2004;
Seoane et al., 2004; Cornforth et al., 2008; Jagani et al., 2008).
Conditional knockout mice of FOXO1, 3, and 4 develop thymic
lymphomas and hemangiomas (Paik et al., 2007; Tothova et al.,
2007). Therefore, FOXO is believed to function as a potential
tumor suppressor.
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It has been shown that IKK, AKT, and ERK directly phospho-
rylate FOXO and induce FOXO ubiquitination and degradation.
Among the three kinases,AKTwas ﬁrst identiﬁed as a FOXOkinase
that phosphorylates FOXO3 at T32, S253, and S315. Phosphory-
lated FOXO3 protein is excluded from entering the nucleus and
binds to 14-3-3 in the cytoplasm (Brunet et al., 1999). In addition
to FOXO3, FOXO1, and FOXO4 are also phoshorylated by AKT
(Tzivion et al., 2011). AKT-phosphorylated FOXO1 and FOXO3
then undergo degradation in a proteasome-dependent manner
(Plas and Thompson, 2003). Speciﬁcally, FOXO1 phosphorylated
byAKT translocates to the cytosolwhere it is ubiquitinatedby Skp2
and subjected to proteasome-dependent degradation (Huang
et al., 2005). We found that IKKβ directly phosphorylates FOXO3
at S644 and induces its ubiquitination and degradation (Hu et al.,
2004). Recently, E3 ligase β-transducing repeat-containing protein
(β-TrCP) is reported to interact with FOXO3 and induces ubiqui-
tination and degradation in an IKKβ-mediated-phosphorylation-
dependent manner (Tsai et al., 2010; Su et al., 2011). Furthermore,
we and others demonstrated that ERK phosphorylates FOXO3
and FOXO1, respectively (Asada et al., 2007; Yang et al., 2008).
We also showed that FOXO3 is phosphorylated by ERK at S294,
S344, and S425, which then undergoes MDM2-mediated ubiq-
uitination, followed by proteasome-dependent degradation (Yang
et al., 2008). MDM2-mediated ubiquitination and degradation
is also observed with FOXO1, which is dependent on the AKT-
mediated phosphorylation (Fu et al., 2009). Interestingly, MDM2
induces mono-ubiquitination of FOXO4,which promotes nuclear
localization of FOXO4, and subsequent polyubiquitination by
Skp2 and degradation (Brenkman et al., 2008). Taken together,
the ubiquitin–proteasome system plays an essential role in reg-
ulating FOXO transcription factors by AKT, ERK, and IKK, and
MDM2, SKP2, and βTrCP are E3 ligases for FOXO ubiquitination
(Figure 1A).
β-CATENIN
β-Catenin is the key protein in both cadherin junction and Wnt
pathway and plays an important role in development and adult
homeostasis as well as tumorigenesis (Cadigan, 2008; Stepniak
et al., 2009). In the Wnt signaling pathway, β-catenin functions as
a transcription co-factor and is involved in the transactivation of
several oncogenic proteins such as c-Myc, CyclinD1, and matrix
metalloproteases (He et al., 1998; Lin et al., 2000; Mosimann et al.,
2009). Glycogen synthase kinase-3β (GSK3β) and casein kinase
1 (CK1) are the major protein kinases regulating the β-catenin
stability. In the absence of Wnt ligand, β-catenin forms a com-
plex with Axin, APC, GSK3β, and CK1 and is phosphorylated by
these kinases. Once phosphorylated,β-catenin undergoes β-TrCP-
mediated ubiquitination and subsequent degradation.WhenWnt
binds to its receptor,Frizzles, and co-receptor,LRP5/6, the receptor
complex recruits Axin–GSK3 complex to cell membrane, releas-
ing β-catenin from the complex for its translocation to the nucleus
where it activates gene transcription with T-cell factor (TCF) and
lymphocyte enhancer factor (LEF).
AKT has been shown to directly phosphorylate GSK3β and
inhibits it (Cross et al., 1995), and therefore, AKT seems to indi-
rectly inhibit β-catenin degradation and inactivation through
inhibition of GSK3β (Monick et al., 2001). In addition to the indi-
rect mechanism, AKT directly mediates the β-catenin stability by
phosphorylating β-catenin at S552. Once phosphorylated by AKT,
β-catenin binds to 14-3-3ζ and is stabilized (Tian et al., 2004; Fang
et al., 2007). In addition to AKT, we also demonstrated that ERK
upregulates β-catenin via inhibition of GSK3β (Ding et al., 2005).
Activated ERK directly interacts with GSK3β and phosphorylates
it at T43. After the phosphorylation by ERK, GSK3 is primed for
subsequent phosphorylation by p90RSK at S9, which inactivates
it. Furthermore, IKK has been shown to be directly involved in
the β-catenin regulation, and IKKα but not IKKβ phosphorylates
FIGURE 1 | Regulation of FOXO3 and β-catenin by AKT, ERK, and
IKK signaling pathway. (A) AKT, ERK, and IKK phosphorylates
FOXO3 at different sites and induces its ubiquitination and
subsequent degradation via SKP2, MDM2, and β-TrCP, respectively.
(B) AKT and ERK phosphorylates GSK3β and inhibit it. GSK3β
phosphorylates catenin and induces its ubiquitination and subsequent
degradation via β-TrCP. Both AKT and IKKα phosphorylate β-catenin
and stabilize it.
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β-catenin and prevent its ubiquitination and degradation (Lam-
berti et al., 2001; Albanese et al., 2003; Carayol and Wang, 2006).
Collectively,β-catenin is another common target of AKT,ERK,and
IKK, demonstrating that the ubiquitin–proteasome system plays a
critical role in these signaling pathways (Figure 1B).
MYELOID CELL LEUKEMIA-1
Myeloid cell leukemia-1 (Mcl-1) is a member of anti-apoptotic
Bcl-2 family proteins which are the central regulators of apoptosis
signaling pathway (Inuzuka et al., 2011a). The Bcl-2 family con-
sist of pro-apoptotic and anti-apoptotic proteins that regulate the
release of apoptogenic proteins such as cytochrome c and Smac
frommitochondria (Youle and Strasser, 2008). Pro-apoptotic Bcl-
2 family proteins include the BH3-only proteins such as Bim, Bid,
Bik, and Bad andmulti-BH domain like Bax and Bak. Bax and Bak
are able to form channels on the surface of mitochondria from
which cytochrome c and Smac are released. Anti-apoptotic Bcl-2
family proteins, which include Bcl-2, Bcl-XL, and Mcl-1, prevent
apoptotic cell death by inhibiting the activation and channel for-
mation of Bax and Bak. In contrast, the BH3-only proteins directly
bind to anti-apoptotic Bcl-2 family proteins and inhibit their
functions. Thus, the balance of anti-apoptotic and pro-apoptotic
proteins determines cell survival and death, and the expression of
anti-apoptotic Bcl-2 family protein is the critical for cell survival.
Among the anti-apoptotic Bcl-2 family proteins, Mcl-1 has a rel-
atively short protein half-life (Nijhawan et al., 2003; Adams and
Cooper, 2007) but its expression is enhanced in various cancer
types (Placzek et al., 2010). Thus, Mcl-1 is an important survival
factor in human cancer.
The primary kinase that regulates Mcl-1 stability is GSK3β. We
and another group reported that GSK3 interacts with and phos-
phorylatesMcl-1 at S155,S159,andT163 (Maurer et al., 2006;Ding
et al., 2007). In addition, phosphorylated Mcl-1 is ubiquitinated
and undergoes proteasome-dependent degradation. So far, three
possible ubiquitin ligases have been identiﬁed for Mcl-1. Mule is
the BH3 domain-containing E3 ligase that was the ﬁrst identiﬁed
as the Mcl-1 ubiquitin ligase by biochemical puriﬁcation (Zhong
et al., 2005). Later, we found that β-TrCP can ubiquitinate and
induce Mcl-1 degradation in GSK3β-mediated-phosphorylation-
dependent manner (Ding et al., 2007). Recently, a tumor suppres-
sor protein, FBW7, is shown to function as aMcl-1 ubiquitin ligase
(Inuzuka et al., 2011b;Wertz et al., 2011). FBW7-induced ubiqui-
tination of Mcl-1 is also dependent the phosphorylation induced
by GSK3β. Although both β-TrCP and FBW7 recognize the same
GSK3β-mediated phosphorylation sites in Mcl-1, the exact roles
of these two ubiquitin ligases under various apoptotic stresses are
unknown.
AKT and ERK have been shown to upregulate Mcl-1 transcrip-
tion (Wang et al., 1999; Booy et al., 2011). In addition, both
PI3K/AKT and MEK/ERK pathways have also been shown to
enhance Mcl-1 protein stability (Derouet et al., 2004). Because
AKT inhibits GSK3β as described above, AKT increases Mcl-1 sta-
bility, at least in part, by inhibiting GSK3β. Indeed, the inhibition
of PI3K induces S159 phosphorylation of Mcl-1 and subsequent
ubiquitination and degradation of Mcl-1, which are blocked by
GSK3 inhibition (Maurer et al., 2006). In addition to GSK3β, it
has been show that ERK phosphorylates Mcl-1 at T92 and T163
(Domina et al., 2004; Ding et al., 2008). In particular, we showed
that ERK-phoshorylatedMcl-1 can interact with Pin1 (Ding et al.,
2008). Pin1 is a peptidyl–prolyl cis/trans isomerase that binds to
speciﬁc pS/T-P motifs and then isomerizes its substrates, result-
ing in their conformational changes. Interestingly, Pin1 stabilizes
Mcl-1 protein after the phosphorylation by ERK, and the expres-
sion of Mcl-1 correlates with Pin1 in multiple human cancer cell
lines (Ding et al., 2008). Thus, ERK and Pin1 cooperatively regu-
late Mcl-1 stability. Regarding IKK, there is no evidence that IKK
is directly involved in Mcl-1 or GSK3β phosphorylation and/or
ubiquitination. However, it has been shown that NF-κB is required
for EGF-induced Mcl-1 induction, suggesting that the IKK–NF-
κB pathway plays a role in Mcl-1 expression or stability (Henson
et al., 2003). Thus, Mcl-1 is a critical apoptosis regulator that is
controlled by the three kinases at the post-translational as well as
transcriptional level (Figure 2A).
SNAIL
Epithelial–mesenchymal transition (EMT) is an important physi-
ological process that converts epithelial cells to mesenchymal cells
which plays an essential role in embryonic development and tis-
sue repair (Nieto,2009). In addition, accumulating evidence shows
that EMT is also critical for cancer metastasis. Epithelial cells lose
cell–cell contacts and gainmigratory properties during EMT.Dur-
ing cancer progression, cancer cells undergo EMT, resulting in
increased motility, invasiveness, and aggressive behavior (Kalluri
andWeinberg, 2009). Snail is a zinc-ﬁnger transcription repressor
that is one of the EMT regulators. Snail family contains Snail1
(Snail), Snail2 (Slug), and Snail3 (Smuc; de Herreros et al., 2010).
Like other EMT regulators, Snail suppresses E-cadherin expres-
sion by binding to its promoter. In addition to EMT, Snail is also
involved in cell death, survival, stem cell, and immune regula-
tion by controlling multiple target genes (Wu and Zhou, 2010).
Downregulation of Snail reduces tumor growth and invasiveness
in xenograft animalmodel (Olmeda et al., 2007).Moreover, Snail is
overexpressed in multiple human cancers, and expression of Snail
is associated with poor cancer prognosis (Peinado et al., 2007).
Therefore, Snail is a critical oncogenic factor.
Snail stability is primarily regulated by GSK3β through the
PI3K–AKTpathway (Song et al., 2009).Wehave shown thatGSK3β
can phosphorylate Snail at six serine residues inwhich two of them
are responsible for Snail stability while the other four are involved
in its nuclear localization (Zhou et al., 2004). First, GSK3β phos-
phorylates Snail at four serine residues to allow its export from the
nucleus. Then, GSK3β phosphorylates the other two sites, result-
ing in β-TrCP-mediated ubiquitination and degradation of Snail.
IKK–NF-κB pathway has also been shown to regulate Snail sta-
bility. Speciﬁcally, NF-κB induces COP9 signalosome 2 (CSN2),
which disrupts the interaction between GSK3 and Snail, resulting
in the inhibition of Snail ubiquitination and subsequent degra-
dation (Wu et al., 2009). So far, there is no evidence to show
that MEK–ERK signaling pathway is directly involved in Snail
stability. However, ERK does play a role in c-Myc-induced EMT
via the inhibition of GSK3β, and there by stabilizing Snail (Cho
et al., 2010). Furthermore, ERK upregulates Snail gene transcrip-
tion though activation of AP-1 transcription factor (Hudson et al.,
2007; Li et al., 2010). Independently of kinases, wild type p53
Frontiers in Oncology | Molecular and Cellular Oncology February 2012 | Volume 2 | Article 15 | 4
Yamaguchi et al. Ubiquitination regulated by survival kinases
FIGURE 2 | Regulation of Mcl-1 and Snail by AKT, ERK, and IKK signaling
pathway. (A) AKT and ERK phosphorylates GSK3β and inhibit it. GSK3β
phosphorylates Mcl-1 and induces its ubiquitination and subsequent
degradation via β-TrCP, Mule, and/or FBW7. ERK also directly phosphorylates
Mcl-1, and phosphorylated Mcl-1 interacts with Pin1, resulting in its
stabilization. The IKK–NF-κB pathway also contributes to Mcl-1 upregulation
but the mechanisms are uncertain. (B) AKT and ERK phosphorylates GSK3β
and inhibit it. GSK3β phosphorylates Snail and induces its nuclear exclusion,
ubiquitination and subsequent degradation via β-TrCP. ERK also upregulates
Snail transcription via AP-1 transcription factor. The IKK–NF-κB pathway
inhibits Snail via upregulation of CSN2, which interferes with the GSK3–Snail
interaction and ubiquitination of Snail.
but not mutant p53 has been shown to interact with and induce
Snail and Slug ubiquitination and degradation (Wang et al., 2009;
Lim et al., 2010). MDM2 functions as an ubiquitin ligase for p53-
induced Snail ubiquitination. Moreover, F-box and leucine-rich
repeat protein 14 (FBXL14) has been shown to interact with and
induce Snail ubiquitination and degradation (Vinas-Castells et al.,
2010). So far, no other kinases have been reported to be involved in
MDM2- or FBXL-mediated Snail ubiquitination. Thus, the three
kinases (AKT, ERK, and IKK) seem to be involved in EMT, at
least in part, by regulating Snail expression through ubiquitination
(Figure 2B).
CONCLUSION AND FUTURE PROSPECT
Recent advances in signal transduction studies have identiﬁed
many key oncogenic kinases and their substrates in cancer progres-
sion, and the signaling pathways associated with these kinases have
been recognized as promising drug targets. Indeed, several kinase
inhibitors have been developed and used in clinic that show high
efﬁcacy and low toxicity (Sharma and Settleman, 2010). However,
several clinical studies have emerged showing that some patients
exhibit little or no response to these targeted drugs, and those who
originally responded the drugs eventually developed resistance.
Although the detailed mechanisms underlying drug resistance are
not fully understood, there is evidence to support that alternative
pathways are being activated in resistant cells to compensate for
the survival signal blocked by targeting agents. For example, EGFR
tyrosine kinase inhibitors (TKIs) are effective drugs for EGFR
mutant lung cancer, but c-MET ampliﬁcation or K-Ras mutation
causes the resistance to TKIs by bypassing the inhibition of sur-
vival signaling (Bean et al., 2007; Linardou et al., 2008). We also
showed that cancer cells with high AKT signaling pathway exhibit
resistance to ERK inhibitors by inhibiting FOXO3 (Yang et al.,
2010). Therefore, in order to develop effective personalized cancer
therapy, it would be essential that we understand the cross-talk
among the multiple oncogenic signaling pathways.
In this review, we introduced AKT, ERK, and IKK as the key
survival kinases for cancer progression and survival.We also men-
tioned that these three pathways have several common targets that
are critical for cancer cell proliferation, survival, and EMT. Because
there aremany other pathways that are activated in human cancers,
we believe that they likely also contribute to the same targets we
described here. These three kinase-signaling pathways may have
other common targets that are critical for cancer progression. We
also introduce some examples of the signaling pathways that are
controlled via the ubiquitin–proteasome system, which seems to
play an essential role in signaling pathway like phosphorylation.
As we described above, inhibition of protein ubiquitination has
been demonstrated to be potential drug targets for cancer therapy.
Moreover, blockade of speciﬁc ubiquitinationmay exhibit less tox-
icity because inhibition of upstream molecules in key oncogenic
signaling pathways may affect numerous signaling pathways and
induce unfavorable side effects. Clearly, further studies for signal-
ing pathways in cancer including post-translational modiﬁcations
are required for the development of effective personalized cancer
therapies.
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